Skip to main content
. Author manuscript; available in PMC: 2022 Aug 17.
Published in final edited form as: Nat Cell Biol. 2022 Feb 17;24(3):373–383. doi: 10.1038/s41556-022-00848-5

Fig. 6|. LSD1 suppression inhibits the proliferation of human cancer cells with active YAP/TAZ.

Fig. 6|

a-c, HLE, SNU-886 and MDA-MB-231 cells carrying doxycycline (Dox) inducible shLSD1 #1 were treated with 1 μg/mL of Dox, and relative cell number was measured. Data are represented as mean ± SD, n = 5 for HLE, n = 6 for SNU-886 and MDA-MB-231, two-way ANOVA.

d-f, HLE, SNU-886 and MDA-MB-231 cells were treated with different concentrations of LSD1 inhibitor SP-2577 and vehicle (DMSO), and relative cell number was measured. Data are represented as mean ± SD, n = 6, two-way ANOVA.

g, Tumor size of MDA-MB-231 xenograft in NSG mice treated with vehicle or SP-2577. Data are represented as mean ± SD, n = 6, two-way ANOVA.

h, Images of tumors derived from the MDA-MB-231 xenografts at the end of the experimental treatment.

i, Body weight of mice during the experimental procedure. No significant difference was found between vehicle and SP-2577 groups (data are presented as mean ± SD, n = 6, P = 0.72, two-way ANOVA).